CCMB Director Rakesh Mishra has informed Vice-President M Venkaiah Naidu that new strains of Covid-19 are less likely to change efficacy of the vaccines.
During a meeting with the Vice-President in Hyderabad, the Director of the Centre for Cellular and Molecular Biology (CCMB) briefed him about the new strains of SARS-CoV-2 found in the United Kingdom and South Africa recently.
Mishra said the mutations in the new strains are less likely to change the efficacy of the vaccines under development. Besides, there is no evidence that suggests the strains are associated with worse outcomes for the patients, although they are more infective. The same disease management strategies are expected to work for the variants too.
The Vice-President sought to know about the likely impact of the new strains in India and the work being carried out on various aspects of the novel corona virus at CCMB.
Mishra informed that investigations were underway to find out whether the new strains are present in India.
Making a presentation to the Vice-President on the work being done at the CCMB on SARS-CoV2, he said that the new strain was 71 per cent more infectious than the other strains. A parallel strain identified in South Africa suggests that it affects younger people more, though more thorough research is required.
He explained that the analysis of the genomes sequenced by CCMB and other researchers in the country has revealed that the initial spread of the virus in India was mainly due to novel India-specific clade, named I/A3i clade. The I/A3i clade had likely entered India from other South-Aast Asian countries.
The analysis by CCMB had further revealed that, with time, the weaker A3i clade was eventually replaced by the A2a clade, which is also the globally prevalent strain.
He said CCMB was the first non-ICMR lab to start testing samples for the novel coronavirus SARS-CoV-2. It also established SoPs for other research institutes and universities for testing, and trained more than 200 personnel from hospitals and testing centres on the testing protocols.
CCMB has tested more than 50,000 samples so far by RT-PCR method. Together, all CSIR labs have tested more than 7,00,000 samples thus far.
Mishra said CCMB’s dry swab Direct RT-PCR method has been approved by ICMR. With partners like Apollo Hospitals, the kits will be manufactured in large numbers and they will reach masses through Spice Health’s mobile testing labs.